vimarsana.com

Latest Breaking News On - சூறாவளி சிகிச்சை இன்க் - Page 5 : vimarsana.com

Lifshitz Law Firm, P C Announces Investigation of AEGN, KSU, LEAF, and MLND

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Lifshitz Law Firm, P.C. Announces Investigation of AEGN, KSU, LEAF, and MLND Lifshitz Law Firm, P.C.April 18, 2021 GMT NEW YORK, April 18, 2021 (GLOBE NEWSWIRE) Aegion Corporation (NASDAQ: AEGN) Lifshitz Law Firm, P.C. announces investigation into possible breach of fiduciary duties in connection with the sale of AEGN to affiliates of New Mountain Capital, L.L.C. for $26.00 per share. If you are a investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780.

SHAREHOLDER ALERT: Rigrodsky Law, P A Reminds Investors of Investigation of NTEC, MLND, CTAC, and ATH Mergers

INVESTIGATION ALERT: Halper Sadeh LLP Investigates TLND, MLND, ORBC, FI; Shareholders are Encouraged to Contact the Firm

INVESTIGATION ALERT: Halper Sadeh LLP Investigates TLND, MLND, ORBC, FI; Shareholders are Encouraged to Contact the Firm April 14, 2021 12:48 ET | Source: Halper Sadeh LLP Halper Sadeh LLP North Brunswick, New Jersey, UNITED STATES NEW YORK, April 14, 2021 (GLOBE NEWSWIRE) Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Talend S.A. (NASDAQ: TLND) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Thoma Bravo for $66.00 in cash per ordinary share and American Depositary Share. If you are a Talend shareholder, . Millendo Therapeutics, Inc. (NASDAQ: MLND) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Tempest Therapeutics, Inc. Upon completion of the merger, Millendo shareholders are expected to own approximately 18

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.